SÃ©bastien L Degorce

List of Publications by Year
in descending order

29 papers	789 citations	516215 16 h-index	525886 27 g-index
36 all docs	36 docs citations	36 times ranked	1373 citing authors

#	Article	IF	Citations
1	The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2H-pyran-4-yl)-1,3-dihydro-2H-imidazo[4,5-c/> Journal of Medicinal Chemistry, 2018, 61, 3823-3841.	2.9	79
2	Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3KÎ² and PI3KÎ´ for the Treatment of PTEN-Deficient Cancers. Journal of Medicinal Chemistry, 2015, 58, 943-962.	2.9	73
3	Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3. Journal of Medicinal Chemistry, 2015, 58, 3611-3625.	2.9	71
4	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase. Journal of Medicinal Chemistry, 2016, 59, 6281-6292.	2.9	56
5	Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines. Journal of Medicinal Chemistry, 2018, 61, 8934-8943.	2.9	56
6	Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1â€“DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. Journal of Medicinal Chemistry, 2021, 64, 14498-14512.	2.9	50
7	Orally Bioavailable and Bloodâ€“Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice. Molecular Cancer Therapeutics, 2018, 17, 1637-1647.	1.9	46
8	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88^{L265P} Diffuse Large B-Cell Lymphoma. Journal of Medicinal Chemistry, 2017, 60, 10071-10091.	2.9	45
9	Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators. Journal of Medicinal Chemistry, 2015, 58, 3522-3533.	2.9	40
10	Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat. ACS Medicinal Chemistry Letters, 2016, 7, 94-99.	1.3	33
11	Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a logD Lowering Twist. ACS Medicinal Chemistry Letters, 2019, 10, 1198-1204.	1.3	33
12	Tricyclic Indazolesâ€”A Novel Class of Selective Estrogen Receptor Degrader Antagonists. Journal of Medicinal Chemistry, 2019, 62, 1593-1608.	2.9	30
13	Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase. Journal of Medicinal Chemistry, 2020, 63, 10460-10473.	2.9	28
14	Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R). Journal of Medicinal Chemistry, 2016, 59, 4859-4866.	2.9	23
15	Discovery of 9-(1-anilinoethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as PI3KÎ²/Î´ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3928-3935.	1.0	18
16	Diversity-orientated synthesis of 3,5-bis(arylamino)pyrazoles. Tetrahedron Letters, 2011, 52, 6719-6722.	0.7	16
17	Analyzing compound and project progress through multi-objective-based compound quality assessment. Future Medicinal Chemistry, 2013, 5, 753-767.	1.1	14
18	Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4. Bioorganic and Medicinal Chemistry, 2018, 26, 913-924.	1.4	13

#	Article	IF	Citations
19	Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88^{L265P} Mutant Diffuse Large B Cell Lymphoma. Journal of Medicinal Chemistry, 2019, 62, 9918-9930.	2.9	13
20	Facile, diversity-orientated one-pot synthesis of ethyl 1,5-disubstituted-1H-1,2,4-triazole-3-carboxylates. Tetrahedron Letters, 2012, 53, 6078-6082.	0.7	11
21	Synthesis of novel, functionalised tricycles utilising the interrupted Pummerer reaction. Tetrahedron Letters, 2016, 57, 152-154.	0.7	8
22	Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3KÎ²/Î´ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2318-2323.	1.0	7
23	One-pot synthesis of bis(amino)-1,2,4-thiadiazoles via direct SNAr. Tetrahedron Letters, 2013, 54, 788-791.	0.7	6
24	Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors. Bioorganic and Medicinal Chemistry, 2020, 28, 115815.	1.4	5
25	Compound Passport Service: supporting corporate collection owners in open innovation. Drug Discovery Today, 2015, 20, 1250-1255.	3.2	4
26	Discovery of a series of 8-(1-phenylpyrrolidin-2-yl)-6-carboxamide-2-morpholino-4H-chromen-4-one as PI3KÎ²/Î´ inhibitors for the treatment of PTEN-deficient tumours. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1949-1954.	1.0	4
27	Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma. Blood, 2016, 128, 777-777.	0.6	2
28	Identification and Optimisation of a Pyrimidopyridone Series of IRAK4 Inhibitors. Bioorganic and Medicinal Chemistry, 2022, 63, 116729.	1.4	1
29	Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFkB Activation in Preclinical Patient-Derived Models of CNS Lymphoma. Blood, 2018, 132, 2840-2840.	0.6	0